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ABSTRACT
Bevacizumab intravitreal injection (IVB) could be detected in plasma that 
might cause an imbalance in the coagulation system. A hypercoagulable state 
is potentially involved in the risk for thrombosis, which is associated with high 
cardiovascular mortality.The objective of the current study was to investigate 
the risk of elevated plasma fibrinogen levelsin hypertensive and normotensive 
patients after IVB in diabetic retinopathy. This study was conducted at Dr. 
Sardjito General Hospital, Yogyakarta from March to June 2019. A total of 64 
patients were enrolled in the study, included of 32 hypertensive and 32 non-
hypertensive patients with diabetic retinopathy who underwent IVB. Patients 
were interviewed and investigated for physical condition and opthalmological 
examination. Fibrinogen levelwas measured before and 1 week after IVB. The 
mean fibrinogen level beforeand after IVB was slightly high in hypertensive 
patients than normotensive but not significantly different(p>0.05). There was 
no significant risk of increased fibrinogen levels after IVB in the hypertension 
group compared to the normotension group in diabetic retinopathy patients. 
The proportion of patients at high risk for cardiovascular disease after IVB was 
not significantly different between both groups.
ABSTRAK
Injeksi intravitreal bevacizumab (IVB) dapat dideteksi dalam plasma, 
yang dapat menyebabkan ketidak seimbangan dalam sistem koagulasi. 
Hiperkoagulasi berpotensi menimbulkan trombosis, yang dikaitkan dengan 
tingginya mortalitas kardiovaskular. Tujuan penelitian ini adalah mengkaji 
risiko peningkatan kadar fibrinogen plasma pasien hipertensi dibandingkan 
normotensi setelah pemberian IVB pada retinopati diabetika. Penelitian 
dilakukan di RSUP Dr. Sardjito, Yogyakarta bulan Maret hingga Juni 2019. 
Total sebanyak 64 pasien, terbagi menjadi kelompok hipertensi (n=32) dan 
normotensi (n=32) terlibat dalam penelitian. Pasien diwawancara dengan 
menggunakan kuesioner kemudian dilakukan pemeriksaan fisik dan status 
oftalmologis. Kadar fibrinogen diperiksa sebelum dan 1 minggu setelah IVB. 
Rerata kadar fibrinogen sebelum dan setelah IVB lebih tinggi pada pasien 
hipertensi dibandingkan pasien normotensi tapi tidak berbeda bermakna 
(p>0.05). Tidak didapatkan risiko peningkatan kadar fibrinogen yang signifikan 
setelah IVB pada kelompok hipertensi dibandingkan normotensi pada pasien 
retinopati diabetika. Proporsi pasien yang berisiko tinggi menderita penyakit 
kardiovaskular setelah injeksi IVB tidak berbeda bermakna antara kedua 
kelompok.
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INTRODUCTION
Intravitreal injection has been 
known since 1911 for retinal detachment 
therapy with injecting air to the 
vitreal cavity. Since then, intravitreal 
injection has been usedto treat various 
intraocular abnormalities.1,2 Frequency 
of intravitreal injection utilization 
increases with the introduction of anti-
vascular endothelial growth factor(anti-
VEGF) therapy. Anti VEGF therapy is used 
widely for the treatment ofchoroidal 
neovascularization (CNV) secondary to 
pathological myopia, idiopathic CNV, 
diabetic retinopathy with macular 
edema, retinal vein occlusion, and 
any other chorioretinal vascular 
abnormalities.2,3
Bevacizumab (Avastin®) works by 
inhibiting the process of angiogenesis, 
a physiological process of new blood 
vessels formation targeting VEGF-A.4 
Bevacizumab also has a role in 
stimulating regression of microvascular 
abnormalities, prevent bleeding and 
inflammation, also stabilize the normal 
vascular.5
The administration of bevacizumab 
can cause an imbalance in the 
coagulation system.Systemic inhibition 
of VEGF-A is associated with an increased 
risk of gastrointestinal bleeding, the 
incidence of arterial thrombosis, and 
death. The appearance of the blood-
retinal barrier restricts the release of 
anti-VEGF agent to the blood flow so 
it can minimize systemic absorption. 
Intravitreal dose of bevacizumab is 400 
times smaller than intravenous dose. So, 
intravitrealinjection is a safer method in 
anti VEGF therapy.2 Several studies have 
shown that intravitreal anti-VEGF agents 
may be detected in a patient's plasma 
because in neovascular abnormalities, 
blood-retinal barrier damage can occur 
thus allowing the absorption of anti-
VEGF into the systemic circulation.6 
Based on this, systemic safety requires 
great attention in patients who received 
anti-VEGF therapy.2
Hypertension is a chronic medical 
condition of the heart and an increase 
in arterial blood pressure.Hypertension 
is the most important risk factor in 
cardiovascular disease-related blood 
coagulation system disorders. Damage 
of the tunica intima in hypertension 
patients causes atherosclerosis, which 
can increase platelet aggregation that 
triggers heart and blood vessel diseases.7
Clotting time, plasma fibrinogen 
levels, and blood viscosity are the most 
common screening tests to determine 
of pre-thrombosis status.2 The effect 
of increasing fibrinogen levels is 
increasing blood viscosity, fibrin clot 
size, tissue deposition, stimulation of 
atherosclerosis, and vascular thickening 
which involved in the pathogenesis 
of cardiovascular thrombosis events.8 
The study aimed to investigate the risk 
of elevated plasma fibrinogen levelsin 
hypertensive and normotensive patients 
after bevacizumab intravitreal injection 
(IVB) in diabetic retinopathy.
MATERIALS AND METHODS
Subjects
This study was conducted atDr. 
Sardjito General Hospital, Yogyakarta, 
Indonesia from Marchto June 2019. 
Subjects were interviewed using 
questionnaires, underwent physical 
and ophthalmological examinations, 
then examined for fibrinogen level 
beforeand one week (6-9 days) after 
IVB. The subjects who met the inclusion 
and exclusion criteria were enrolled in 
the study. The inclusion criteria were 
patients aged 40-65 years old, can be 
interviewed, are willing to do laboratory 
tests and controlling examination 
on schedule. The exclusion criteria 
included anticoagulant therapy (heparin 
or warfarin), history of coagulation 
disorders, and patients whose blood 
samples could not be carried out by a 
laboratory test. The subjects were then 
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grouped into two groups included of 
32 hypertensive and 32 normotensive 
patients with diabetic retinopathy who 
underwentIVB. The hypertension group 
consisted of diabetic patients with blood 
pressure at examination ≥140/90 mmHg 
and have history of hypertension. The 
normotension group consisted of diabetic 
patients with blood pressure <140/90 
mmHg and have never been diagnosed 
with hypertension by a medical doctor.
Fibrinogen analysis
Blood samples were drawn from 
the mediancubital vein using sterile 
disposable puncture needles, and placed 
in 2mL tubescontaining trisodium citrate 
3.2% (0.109M) which have a ratio of 9:1. 
The sample were centrifuged for 15 min 
at 3500 rpm. Citrate blood was prepared 
into plasma citrate then fibrinogen 
was immediately examined using a full 
automatic coagulometer ACLTop 300 
(IL).
Statistical analysis
Data were presented as mean ± 
standard deviation (SD) or frequency or 
percentage. The different of the plasma 
fibrinogen levels and other variables 
of the hypertensive and normotensive 
groups was analysis using student t 
test.  A p value < 0.05 was considered as 
significant.
RESULTS
Patients demographic and clinical 
characteristics are summarizedinTABLE 
1. There was no significant differences in 
baseline values between groups (p> 0.05) 
except for smoking history (p = 0.039).
TABLE1. Demographic and clinical characteristic subjects
Characteristics Hypertension Normotension p
Age(years) 55.78±5.14 53.53±6.94 0.146
Gender
•	 Male 13(40.6) 20(62.5) 0.080
•	 Female 19(59.4) 12(37.5)
Visus (logMar) 0.49±1.64 1.04±0.87 0.098
Duration of DM (years) 9.50±6.49 9.87±7.32 0.946
Regular antidiabetics
•	 Yes 30(93.8) 31(96.9)
•	 No 2(6.2) 1(3.1) 1.000
Smoking history 4(12.5) 0(0.0) 0.039
Dyslipidemia 13(40.6) 11(36.7) 0.749
BMI 24.39±3.07 23.36±3.58 0.221
PE History
•	 Everyday 10(31.3) 4(12.5)
•	 1-3time/week 6(18.8) 6(18.8)
•	 Infrequently 16(50.0) 22(68.8) 0.172
Fibrinogen level before IVB (mg/dL) 364.22±47.48 352.59±43.57 0.311
Total of  IVB 3.00±2.87 4.031±4.81 0.743
IOP before IVB (mmHg) 13.17±2.78 13.00±3.41 0.802
DM = Diabetes Melitus; BMI = Body Mass Index; IVB = Intravitreal Bevacizumab; PE = 
Physical Exercise; IOP= Intraocular  Pressure. Data on age, vision, duration of DM, BMI, 
pre IVB fibrinogen level, IVB count and IOP pre IVB are displayed as mean ± standard 
deviation (SD). While data on sex, regular antidiabetics, smoking history, dyslipidemia 
and PE history werepresented in frequency and percentage (n,%)
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TABLE 2 shows that fibrinogen levels 
before and after IVB. In the hypertension 
group had the fibrinogen levels higher 
than that the normotension group. 
However,it was notsignificantly different 
(p> 0.05). 
Patients with elevated fibrinogen 
levels were slightly higher in the 
hypertension group than normotension 
group (TABLE 3), with an RR value of 
1.182 and 95% CI (0.626-2.233). However, 
there was no risk relationship associated 
with an increase in fibrinogen levels in 
the both groups.
TABLE 2. Fibrinogen levelbefore and after IVB in hypertension 
and normotension groups
Group
Fibrinogen levels (mean±SD)
p
Before IVB After IVB 
Hypertension(n=32) 364.22±47.48 363.06±53.32 0.882
Normotension(n=32) 352.59±43.57 346.18±51.27 0.237
p 0.311 0.103
SD = standard deviation
TABLE 3. Proportion of patients who had elevatedfibrinogen level 
afterIVB 
Group
Fibrinogen levels [n (%)]
RR (95 %CI)
Elevated Unelevated
Hypertension (n=32) 13 (40.6) 19 (59.4) 1.182
(0.626-2.233)Normotension(n=32) 11 (34.4) 21 (65.6)
RR = Relative Risk; CI=Confidence Interval
TABLE 4. Relative Risks (RR) of subjects related to cardiovascular 
disease after IVB
Group
Risk of cardiovascular 
disease [n (%)] RR (95 %CI)
High Low
Hypertension (n=21) 19 (90.5) 2 (9.5) 1.131
(0.847-1.509)Normotension(n=15) 12 (80.0) 3 (20.0)
RR = Relative Risk; CI=Confidence Interval; High Risk= fibrinogen 
levels≥350 mg/dL, Low Risk= fibrinogenlevels≤290 mg/dL)
The subjects consisted of both groups 
having high risk (fibrinogen levels ≥350 
mg/dL) and low risk (fibrinogen levels 
≤290 mg/dL) of cardiovascular disease.
TABLE 4 shows, hypertension condition 
did not increase the risk of cardiovascular 
disease. TABLE 5 compares the risk of 
increasing fibrinogen levels in patients 
who have received first IVB and 
more than three times. There was no 
significantly different found in increased 
level of fibrinogen in subjects from the 
both groups. This showed, repeated or 
chronic IVB administration did not raise 
the risk of increased fibrinogen level 
with RR value of 1.064 and 95%CI (0.529-
2.140).
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TABLE 5. Risk of elevated fibrinogen level based on frequency of IVB administration
Variable
Fibrinogen level [n (%)]
RR (95 %CI) p
Elevated Unelevated
IVB > 3 time (n=22) 9 (40.9) 13 (59.1) 1.064
(0.529-2.140) 0.863First IVB(n=26) 10 (38.5) 16 (61.5)
RR = Relative Risk; CI=Confidence Interval
DISCUSSION
There were four study subjects with 
smoking history in the hypertension 
group. Several studies showed a close 
relationship between increased blood 
pressure and history of smoking. 
Older men with history of moderate 
to severe smoking have significantly 
higher systolic blood pressure than non-
smokers.9
Fibrinogen levels in the hypertension 
group, were slightly higher than the 
normotension group as shown in TABLE 
2. Proportion test result showed that 
there was no risk relationship between 
increased level of fibrinogen in the two 
groups. Hypertension is not only one 
of the most important risk factor for 
cardiovascular disease, but also the most 
modifiable risk factor for stroke. There 
is a change in the blood clotting system 
in hypertensive patients.7 Fibrinogen 
was identified as the major independent 
risk factor for cardiovascular disease.10 
Eldour et al,7 found that plasma 
fibrinogen level significantly higher in 
hypertensive patients than in the control 
group. Secchi et al,11 reported a strong 
and independent relationship between 
fibrinogen and the severity of damage 
correlated with hypertension in different 
target organs.
Majeed et al,8 mentioned that 
fibrinogen level can affect the prognosis 
of hypertensive patients. Hypertensive 
patients with plasma fibrinogen 
more than 350 mg/dL have a risk of 
cardiovascular disease 12 times greater 
than hypertensive patients who have 
fibrinogen under 290 mg/dL.12 TABLE 4 
showed that the hypertension condition 
does not increase the high risk of 
cardiovascular disease. Majeed et al,8 
also showed that there is no significant 
difference in fibrinogen levels between 
the hypertension group and the 
normotensive population. This result 
can be caused by differences in patient’s 
blood pressure, smaller sample size, and 
the presence of antihypertensive drugs 
in the hemostatic system.
Bevacizumab vitreous half-life 
has been estimated at 11.3 days after 
intravitreal injection.13,14 The maximum 
serum concentration (3.3 µg/mL) 
was reached in 8 days after IVB, with 
concentration that remained above 
1µg/mL after 29 days. Bevacizumab 
elimination from aqueous humor and 
serum was the same as vitreous which 
have a half-life of 4.88 days and 6.86 
days.15,16 The systemic concentration of 
bevacizumab after 1.25 mg intravitreal 
injection ranged from 59.8 to 86.5 ng/mL 
and its ability to bind with the VEGF was 
significantly lower than ranibizumab 
due to the maturation of bevacizumab 
affinity was 14-100 times lower.17,18
The causes of fibrinogen levels after 
IVB were not significantly different 
between the two study groups might be 
caused by very low doses, intravitreal 
routes of administration (there is a blood-
retinal barrier) and low bevacizumab 
affinity. Insignificant fibrinogen levels 
between the two groups might also be 
caused by condition of diabetes mellitus 
of the subjects. All subjects in this study 
were diabetes mellitus sufferers who had 
both hypertension and normotension. 
Increased level of fibrinogen or 
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hyperfibrinogenemia, can occur in 
people with diabetes mellitus whether 
they are related to hypertension or not, 
depending on the condition of diabetes 
itself. 
The various possible mechanisms 
for hyperfibrinogenemia in diabetics 
could be that a procoagulant state often 
exists in people of diabetes. There is an 
increase in some coagulation factors 
such as plasminogen activator inhibitor 
1, von-Willebrand factor, fibrinogen, 
factor VII and thrombin-antithrombin 
complexes particularly in association 
with macrovascular and microvascular 
disease and glycemiccontrol. Plasma 
levels of lipoprotein(a) [Lp(a)] are 
elevated in people with diabetes, 
particularly those with poor glycemic 
control. The Lp(a) molecule is formed 
by the assembly of at least two major 
proteins, a molecule of apoB100 
covalently linked to a molecule of 
apolipoprotein(a) [APO(a)] by a single 
disulfide bridge. It is structurally 
similar to low-density lipoprotein (LDL) 
in protein and lipid composition, the 
essential difference between the two 
being APO(a). APO(a), a glycoprotein 
structurally similar to plasminogen, the 
precursor of plasmin can bind to fibrin, 
the membrane protein of endothelial cells 
and monocytes. This inhibit plasminogen 
binding and plasmin generation which 
leads to decreased fibrinolysis and 
delayed thrombolysis and contributes to 
the accumulation of Lp(a) and fibrin at 
the sites of vascular injury. Lp(a) has a 
major role in diabetes and its vascular 
complications by decreasing fibrinolysis 
and thus increasing plasma fibrinogen 
levels.19
The correlation between glycemic 
control and fibrinogen levels could be 
due to two reasons. Either glycosylate 
fibrinogen is less susceptible to plasmin 
degradation or relative insulin deficiency 
in diabetic’s results in differential protein 
synthesis i.e., 29% decrease in albumin 
synthesis and 50% increase in fibrinogen 
synthesis.19,20
The limitation of this study was that 
there was no further investigation of 
the diabetes mellitus conditionsuch as 
duration of illness, adherence to taking 
medication and HbA1c levels), severity 
of hypertension and adherence in taking 
antihypertensive drugs.
CONCLUSION
There is no significant risk of 
increased fibrinogen levels after IVB 
in the hypertension group compared 
to the normotension group in diabetic 
retinopathy patients. Further research 
are suggested to investigatethe relatioship 
of diabetes mellitus conditions such as 
duration of illness, compliance with 
taking medication and HbA1C levels, 
severity of hypertension and adherence 
in taking antihypertensive drugs.
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